Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome
Purpose. To report an unusual presentation of commercial cannabidiol (CBD) oil-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS-TEN). Methods. A 56-year-old woman presented with acute onset of a diffuse, blistering, maculopapular rash with over 30% total body surface area (BSA) invol...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Ophthalmological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2020/6760272 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547684112662528 |
|---|---|
| author | Han Y. Yin Nicholas Hadjokas Kanish Mirchia Robert Swan Samuel Alpert |
| author_facet | Han Y. Yin Nicholas Hadjokas Kanish Mirchia Robert Swan Samuel Alpert |
| author_sort | Han Y. Yin |
| collection | DOAJ |
| description | Purpose. To report an unusual presentation of commercial cannabidiol (CBD) oil-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS-TEN). Methods. A 56-year-old woman presented with acute onset of a diffuse, blistering, maculopapular rash with over 30% total body surface area (BSA) involvement two days after taking CBD oil sublingually for chronic pain. Biopsy confirmed SJS-TEN. Ophthalmology was consulted and mild eye involvement was found. She was started on topical cyclosporine, prednisone, moxifloxacin, and erythromycin ointment to prevent progression, which was successful. She was otherwise treated with supportive therapy in the intensive care burn unit and ultimately passed away from septic shock. Conclusion. In this case, we described an unusual drug-induced SJS from a commercial, non-FDA-regulated cannabis product. The use of a commercial CBD product should be cautioned due to potential for series of drug reactions to the cannabis product and the risk for reaction to other unregulated other pharmacological components. |
| format | Article |
| id | doaj-art-0b178e6934db465eb41fec46c09ba41b |
| institution | Kabale University |
| issn | 2090-6722 2090-6730 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Ophthalmological Medicine |
| spelling | doaj-art-0b178e6934db465eb41fec46c09ba41b2025-02-03T06:43:39ZengWileyCase Reports in Ophthalmological Medicine2090-67222090-67302020-01-01202010.1155/2020/67602726760272Commercial Cannabinoid Oil-Induced Stevens-Johnson SyndromeHan Y. Yin0Nicholas Hadjokas1Kanish Mirchia2Robert Swan3Samuel Alpert4Department of Ophthalmology and Visual Sciences, SUNY Upstate Medical University, Syracuse, NY, USADepartment of Ophthalmology and Visual Sciences, SUNY Upstate Medical University, Syracuse, NY, USADepartment of Pathology, SUNY Upstate Medical University, Syracuse, NY, USADepartment of Ophthalmology and Visual Sciences, SUNY Upstate Medical University, Syracuse, NY, USADepartment of Ophthalmology and Visual Sciences, SUNY Upstate Medical University, Syracuse, NY, USAPurpose. To report an unusual presentation of commercial cannabidiol (CBD) oil-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS-TEN). Methods. A 56-year-old woman presented with acute onset of a diffuse, blistering, maculopapular rash with over 30% total body surface area (BSA) involvement two days after taking CBD oil sublingually for chronic pain. Biopsy confirmed SJS-TEN. Ophthalmology was consulted and mild eye involvement was found. She was started on topical cyclosporine, prednisone, moxifloxacin, and erythromycin ointment to prevent progression, which was successful. She was otherwise treated with supportive therapy in the intensive care burn unit and ultimately passed away from septic shock. Conclusion. In this case, we described an unusual drug-induced SJS from a commercial, non-FDA-regulated cannabis product. The use of a commercial CBD product should be cautioned due to potential for series of drug reactions to the cannabis product and the risk for reaction to other unregulated other pharmacological components.http://dx.doi.org/10.1155/2020/6760272 |
| spellingShingle | Han Y. Yin Nicholas Hadjokas Kanish Mirchia Robert Swan Samuel Alpert Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome Case Reports in Ophthalmological Medicine |
| title | Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome |
| title_full | Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome |
| title_fullStr | Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome |
| title_full_unstemmed | Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome |
| title_short | Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome |
| title_sort | commercial cannabinoid oil induced stevens johnson syndrome |
| url | http://dx.doi.org/10.1155/2020/6760272 |
| work_keys_str_mv | AT hanyyin commercialcannabinoidoilinducedstevensjohnsonsyndrome AT nicholashadjokas commercialcannabinoidoilinducedstevensjohnsonsyndrome AT kanishmirchia commercialcannabinoidoilinducedstevensjohnsonsyndrome AT robertswan commercialcannabinoidoilinducedstevensjohnsonsyndrome AT samuelalpert commercialcannabinoidoilinducedstevensjohnsonsyndrome |